Symbols / GTBP $0.42 +2.51%
GTBP Chart
About
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.41M |
| Enterprise Value | 6.60M | Income | -34.45M | Sales | — |
| Book/sh | 0.23 | Cash/sh | 0.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.04 | PEG | — |
| P/S | — | P/B | 1.87 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 2.94 |
| Current Ratio | 3.50 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -6.68 | EPS next Y | -10.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 07:00 | ROA | -125.85% |
| ROE | -13.77% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.55M |
| Shs Float | 30.83M | Short Float | 7.85% | Short Ratio | 1.56 |
| Short Interest | — | 52W High | 3.85 | 52W Low | 0.39 |
| Beta | 1.19 | Avg Volume | 1.53M | Volume | 526.63K |
| Target Price | $3.00 | Recom | Strong_buy | Prev Close | $0.41 |
| Price | $0.42 | Change | 2.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.43
Latest analyst target
3. DCF / Fair value
$-6.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.43
Low
$3.00
High
$3.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-12-02 | init | Roth MKM | — → Buy | $11 |
- GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 16 Mar 2026 16
- New immune-based drug to test B7-H3 solid tumors across 7 cancers in trial - Stock Titan hu, 15 Jan 2026 08
- GT Biopharma (GTBP) Raised to Buy: Key Information You Need - Bitget Mon, 16 Mar 2026 02
- GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance hu, 12 Mar 2026 13
- Cancer trial firm GT Biopharma says $9M cash funds work into late 2026 - Stock Titan Mon, 02 Mar 2026 12
- GT Biopharma stock rises as Phase 1 trial advances to higher dose - Investing.com Wed, 19 Nov 2025 08
- GT Biopharma registers 120.6M shares for resale by selling stockholders - MSN Wed, 11 Mar 2026 19
- GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative Wed, 08 Oct 2025 07
- GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits hu, 09 Oct 2025 02
- GT Biopharma (GTBP) Develops 'Hammer Chart Pattern': Is It an Opportunity to Buy at the Bottom? - Bitget Wed, 11 Mar 2026 23
- FDA clears GTB-5550 trial for advanced prostate and other solid tumors - Stock Titan ue, 03 Feb 2026 08
- GT Biopharma holders waive redemption rights on Series L preferred stock - Investing.com ue, 23 Sep 2025 07
- GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Yahoo Finance Wed, 19 Nov 2025 08
- Immuno-oncology GT Biopharma to detail TriKE platform for Toronto investors - Stock Titan ue, 17 Feb 2026 08
- EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance Wed, 08 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -730.00K | -13.96M | -12.78M | -20.96M |
| TotalUnusualItems | -27.50M | 800.00K | 5.39M | 89.00K |
| TotalUnusualItemsExcludingGoodwill | -27.50M | 800.00K | 5.39M | 89.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -28.35M | -13.16M | -7.60M | -20.88M |
| EBITDA | -28.23M | -13.16M | -7.38M | -20.88M |
| EBIT | -28.23M | -13.16M | -7.38M | -20.88M |
| NetInterestIncome | -4.00K | 402.00K | 567.00K | 284.00K |
| InterestExpense | 127.00K | 0.00 | 213.00K | 8.00K |
| InterestIncome | 123.00K | 402.00K | 780.00K | 292.00K |
| NormalizedIncome | -857.00K | -13.96M | -12.99M | -20.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -28.35M | -13.16M | -7.60M | -20.88M |
| TotalExpenses | 12.42M | 14.36M | 13.58M | 21.26M |
| TotalOperatingIncomeAsReported | -12.42M | -14.36M | -13.58M | -21.26M |
| DilutedAverageShares | 1.90M | 1.35M | 1.07M | 938.52K |
| BasicAverageShares | 1.90M | 1.35M | 1.07M | 938.52K |
| DilutedEPS | -6.94 | -5.64 | -19.46 | -61.80 |
| BasicEPS | -6.94 | -5.64 | -19.46 | -61.80 |
| DilutedNIAvailtoComStockholders | -34.45M | -13.16M | -7.60M | -20.88M |
| NetIncomeCommonStockholders | -34.45M | -13.16M | -7.60M | -20.88M |
| OtherunderPreferredStockDividend | 5.78M | 0.00 | ||
| PreferredStockDividends | 320.00K | |||
| NetIncome | -28.35M | -13.16M | -7.60M | -20.88M |
| NetIncomeIncludingNoncontrollingInterests | -28.35M | -13.16M | -7.60M | -20.88M |
| NetIncomeContinuousOperations | -28.35M | -13.16M | -7.60M | -20.88M |
| PretaxIncome | -28.35M | -13.16M | -7.60M | -20.88M |
| OtherIncomeExpense | -15.93M | 800.00K | 5.41M | 89.00K |
| OtherNonOperatingIncomeExpenses | 11.57M | 20.00K | ||
| SpecialIncomeCharges | -27.74M | 0.00 | 547.00K | 0.00 |
| OtherSpecialCharges | 27.74M | -547.00K | ||
| GainOnSaleOfSecurity | 241.00K | 800.00K | 4.84M | 89.00K |
| NetNonOperatingInterestIncomeExpense | -4.00K | 402.00K | 567.00K | 284.00K |
| InterestExpenseNonOperating | 127.00K | 0.00 | 213.00K | 8.00K |
| InterestIncomeNonOperating | 123.00K | 402.00K | 780.00K | 292.00K |
| OperatingIncome | -12.42M | -14.36M | -13.58M | -21.26M |
| OperatingExpense | 12.42M | 14.36M | 13.58M | 21.26M |
| ResearchAndDevelopment | 3.47M | 5.80M | 6.47M | 8.81M |
| SellingGeneralAndAdministration | 8.95M | 8.57M | 7.11M | 12.45M |
| GeneralAndAdministrativeExpense | 47.92M | |||
| OtherGandA | 47.92M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| PreferredSharesNumber | 121.23K | 121.23K | 121.23K | 121.23K |
| OrdinarySharesNumber | 25.53M | 2.23M | 1.38M | 1.09M |
| ShareIssued | 25.53M | 2.23M | 1.38M | 1.09M |
| TotalDebt | 0.00 | 58.00K | 174.00K | 31.00K |
| TangibleBookValue | 5.79M | -1.67M | 7.47M | 11.73M |
| InvestedCapital | 5.79M | -1.67M | 7.47M | 11.73M |
| WorkingCapital | 5.79M | -1.67M | 7.42M | 11.62M |
| NetTangibleAssets | 5.79M | -1.67M | 7.48M | 11.73M |
| CapitalLeaseObligations | 0.00 | 58.00K | 174.00K | 0.00 |
| CommonStockEquity | 5.79M | -1.67M | 7.47M | 11.73M |
| PreferredStockEquity | 1.00K | 1.00K | 1.00K | 1.00K |
| TotalCapitalization | 5.79M | -1.67M | 7.48M | 11.73M |
| TotalEquityGrossMinorityInterest | 5.79M | -1.67M | 7.48M | 11.73M |
| StockholdersEquity | 5.79M | -1.67M | 7.48M | 11.73M |
| RetainedEarnings | -723.90M | -695.23M | -682.07M | -674.47M |
| AdditionalPaidInCapital | 729.66M | 693.55M | 689.54M | 686.17M |
| CapitalStock | 27.00K | 3.00K | 2.00K | 34.00K |
| CommonStock | 26.00K | 2.00K | 1.00K | 33.00K |
| PreferredStock | 1.00K | 1.00K | 1.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 2.32M | 5.90M | 6.63M | 5.00M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 64.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 64.00K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 64.00K | 0.00 | |
| CurrentLiabilities | 2.32M | 5.90M | 6.63M | 4.94M |
| OtherCurrentLiabilities | 11.00K | 252.00K | 1.05M | 19.00K |
| CurrentDebtAndCapitalLeaseObligation | 58.00K | 110.00K | 31.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 58.00K | 110.00K | 0.00 |
| CurrentDebt | 31.00K | |||
| LineOfCredit | 0.00 | 31.00K | ||
| PayablesAndAccruedExpenses | 2.31M | 5.65M | 5.52M | 4.81M |
| CurrentAccruedExpenses | 1.56M | 1.80M | 1.20M | 1.67M |
| InterestPayable | 0.00 | |||
| Payables | 748.00K | 3.85M | 4.33M | 3.14M |
| AccountsPayable | 748.00K | 3.85M | 4.33M | 3.14M |
| TotalAssets | 8.11M | 4.23M | 14.11M | 16.74M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 53.00K | 174.00K |
| NonCurrentPrepaidAssets | 0.00 | 9.00K | 0.00 | |
| NetPPE | 0.00 | 53.00K | 165.00K | 0.00 |
| GrossPPE | 0.00 | 53.00K | 165.00K | 0.00 |
| OtherProperties | 53.00K | 165.00K | ||
| CurrentAssets | 8.11M | 4.23M | 14.06M | 16.56M |
| OtherCurrentAssets | 567.00K | 188.00K | 84.00K | 54.00K |
| CurrentDeferredAssets | 634.00K | 0.00 | ||
| RestrictedCash | 94.00K | 93.00K | 0.00 | |
| PrepaidAssets | 190.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 6.81M | 3.95M | 13.97M | 16.51M |
| OtherShortTermInvestments | 0.00 | 12.89M | 10.84M | 23.01M |
| CashAndCashEquivalents | 6.81M | 3.95M | 1.08M | 5.67M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.91M | -12.90M | -8.85M | -15.22M |
| RepurchaseOfCapitalStock | 0.00 | -224.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 1.21M | ||
| IssuanceOfCapitalStock | 10.51M | 2.98M | 6.27M | 0.00 |
| InterestPaidSupplementalData | 0.00 | 0.00 | 213.00K | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 6.91M | 4.04M | 1.08M | 5.67M |
| BeginningCashPosition | 4.04M | 1.08M | 5.67M | 8.97M |
| ChangesInCash | 2.86M | 2.96M | -4.59M | -3.30M |
| FinancingCashFlow | 15.78M | 2.98M | 6.27M | -224.00K |
| CashFlowFromContinuingFinancingActivities | 15.78M | 2.98M | 6.27M | -224.00K |
| ProceedsFromStockOptionExercised | 5.50M | 0.00 | 0.00 | 16.43M |
| CashDividendsPaid | -229.00K | 0.00 | ||
| PreferredStockDividendPaid | -229.00K | 0.00 | ||
| NetPreferredStockIssuance | 10.51M | |||
| PreferredStockIssuance | 10.51M | |||
| NetCommonStockIssuance | 0.00 | 2.98M | 6.27M | -224.00K |
| CommonStockPayments | 0.00 | -224.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 2.98M | 6.27M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 1.21M | ||
| NetLongTermDebtIssuance | 0.00 | 1.21M | ||
| LongTermDebtIssuance | 0.00 | 1.21M | ||
| InvestingCashFlow | 0.00 | 12.89M | -2.01M | 12.14M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 12.89M | -2.01M | 12.14M |
| NetInvestmentPurchaseAndSale | 0.00 | 12.89M | -2.01M | 12.14M |
| SaleOfInvestment | 0.00 | 12.89M | ||
| PurchaseOfInvestment | -23.04M | |||
| OperatingCashFlow | -12.91M | -12.90M | -8.85M | -15.22M |
| CashFlowFromContinuingOperatingActivities | -12.91M | -12.90M | -8.85M | -15.22M |
| ChangeInWorkingCapital | -920.00K | 828.00K | 1.94M | -1.99M |
| ChangeInOtherCurrentLiabilities | 0.00 | -58.00K | -116.00K | -86.00K |
| ChangeInOtherCurrentAssets | 0.00 | 53.00K | 112.00K | 95.00K |
| ChangeInPayablesAndAccruedExpense | -1.30M | 937.00K | 1.96M | -2.03M |
| ChangeInAccruedExpense | 0.00 | 689.00K | ||
| ChangeInInterestPayable | 0.00 | 689.00K | ||
| ChangeInPayable | -2.03M | 7.08M | ||
| ChangeInAccountPayable | -2.03M | 7.08M | ||
| ChangeInPrepaidAssets | 377.00K | -104.00K | -21.00K | 127.00K |
| OtherNonCashItems | 17.32M | 112.00K | 130.00K | 720.00K |
| StockBasedCompensation | 432.00K | 230.00K | 2.20M | 7.65M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -48.00K | 30.00K | 29.00K |
| OperatingGainsLosses | -1.40M | -800.00K | -5.34M | -150.00K |
| GainLossOnInvestmentSecurities | -197.00K | -800.00K | -4.80M | -119.00K |
| GainLossOnSaleOfPPE | 112.00K | 95.00K | ||
| NetIncomeFromContinuingOperations | -28.35M | -13.16M | -7.60M | -20.88M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GTBP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|